| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jari Tiihonen, Antti Tanskanen, J Simon Bell, Jessica L Dawson, Vesa Kataja, Heidi Taipal. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. The lancet. Psychiatry. 2022-03-25. PMID:35334224. |
long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in finland. |
2022-03-25 |
2023-08-13 |
Not clear |
| Jari Tiihonen, Antti Tanskanen, J Simon Bell, Jessica L Dawson, Vesa Kataja, Heidi Taipal. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. The lancet. Psychiatry. 2022-03-25. PMID:35334224. |
clozapine is the most efficacious treatment for schizophrenia and is associated with lower overall mortality than are other antipsychotic drugs, despite the risk of agranulocytosis. |
2022-03-25 |
2023-08-13 |
Not clear |
| Jose de Leo. Precision psychiatry: The complexity of personalizing antipsychotic dosing. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 58. 2022-03-22. PMID:35314415. |
clozapine maintenance dosing is based on the dose needed to reach 350 ng/ml (the minimum plasma therapeutic concentration in treatment-resistant schizophrenia). |
2022-03-22 |
2023-08-13 |
Not clear |
| Gábor Nadubinszky, Béla Székács, Zoltán Rihme. [Influence of psychiatric diseases and psychiatric medication to the severity of clinical outcome of COVID-19]. Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata. vol 37. issue 1. 2022-03-21. PMID:35311693. |
clozapine (an antipsychotic used in therapy of treatment resistant schizophrenia) seems to decrease the likelihood of recovery in covid-19 patients, however admi nistration of antidepressant medications appears to increase it. |
2022-03-21 |
2023-08-13 |
Not clear |
| Hana Hribkova, Ondrej Svoboda, Elis Bartecku, Jana Zelinkova, Jana Horinkova, Lubica Lacinova, Martin Piskacek, Bretislav Lipovy, Ivo Provaznik, Joel C Glover, Tomas Kasparek, Yuh-Man Su. Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients. Frontiers in cellular neuroscience. vol 16. 2022-03-14. PMID:35281293. |
clozapine reverses dysfunction of glutamatergic neurons derived from clozapine-responsive schizophrenia patients. |
2022-03-14 |
2023-08-13 |
Not clear |
| Hana Hribkova, Ondrej Svoboda, Elis Bartecku, Jana Zelinkova, Jana Horinkova, Lubica Lacinova, Martin Piskacek, Bretislav Lipovy, Ivo Provaznik, Joel C Glover, Tomas Kasparek, Yuh-Man Su. Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients. Frontiers in cellular neuroscience. vol 16. 2022-03-14. PMID:35281293. |
we employed glutamatergic neurons derived from induced pluripotent stem cells (ipsc) obtained from schizophrenia patients with known histories of response to clozapine and healthy controls to decipher the mechanisms of action of clozapine, spanning from molecular (transcriptomic profiling) and cellular (electrophysiology) levels to observed clinical effects in living patients. |
2022-03-14 |
2023-08-13 |
Not clear |
| Daniela Fonseca de Freitas, India Patel, Giouliana Kadra-Scalzo, Megan Pritchard, Hitesh Shetty, Matthew Broadbent, Rashmi Patel, Johnny Downs, Aviv Segev, Mizanur Khondoker, James H MacCabe, Kamaldeep Bhui, Richard D Haye. Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records. Social psychiatry and psychiatric epidemiology. 2022-03-05. PMID:35246709. |
ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records. |
2022-03-05 |
2023-08-13 |
Not clear |
| Daniela Fonseca de Freitas, India Patel, Giouliana Kadra-Scalzo, Megan Pritchard, Hitesh Shetty, Matthew Broadbent, Rashmi Patel, Johnny Downs, Aviv Segev, Mizanur Khondoker, James H MacCabe, Kamaldeep Bhui, Richard D Haye. Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records. Social psychiatry and psychiatric epidemiology. 2022-03-05. PMID:35246709. |
clozapine is the most effective intervention for treatment-resistant schizophrenia (trs). |
2022-03-05 |
2023-08-13 |
Not clear |
| Fanni Krajner, Laila Hadaya, Grant McQueen, Kyra-Verena Sendt, Amy Gillespie, Alessia Avila, John Lally, Emily P Hedges, Kelly Diederen, Oliver D Howes, Gareth J Barker, David J Lythgoe, Matthew J Kempton, Philip McGuire, James H MacCabe, Alice Egerto. Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia. NPJ schizophrenia. vol 8. issue 1. 2022-03-03. PMID:35236831. |
subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia. |
2022-03-03 |
2023-08-13 |
Not clear |
| Fanni Krajner, Laila Hadaya, Grant McQueen, Kyra-Verena Sendt, Amy Gillespie, Alessia Avila, John Lally, Emily P Hedges, Kelly Diederen, Oliver D Howes, Gareth J Barker, David J Lythgoe, Matthew J Kempton, Philip McGuire, James H MacCabe, Alice Egerto. Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia. NPJ schizophrenia. vol 8. issue 1. 2022-03-03. PMID:35236831. |
data were acquired in 24 patients with treatment-resistant schizophrenia before and 12 weeks after switching to clozapine. |
2022-03-03 |
2023-08-13 |
Not clear |
| Kentaro Mizuno, Emiko Mizuno, Akira Suekane, Toshiaki Shiratsuch. Efficacy of clozapine for long-stay patients with treatment-resistant schizophrenia: 4-year observational study. Neuropsychopharmacology reports. 2022-03-02. PMID:35234369. |
efficacy of clozapine for long-stay patients with treatment-resistant schizophrenia: 4-year observational study. |
2022-03-02 |
2023-08-13 |
Not clear |
| Kentaro Mizuno, Emiko Mizuno, Akira Suekane, Toshiaki Shiratsuch. Efficacy of clozapine for long-stay patients with treatment-resistant schizophrenia: 4-year observational study. Neuropsychopharmacology reports. 2022-03-02. PMID:35234369. |
this study evaluated the efficacy of clozapine in treating long-stay patients with treatment-resistant schizophrenia to reduce the frequency and duration of readmissions postdischarge. |
2022-03-02 |
2023-08-13 |
Not clear |
| Daniela Fonseca de Freitas, Giouliana Kadra-Scalzo, Deborah Agbedjro, Emma Francis, Isobel Ridler, Megan Pritchard, Hitesh Shetty, Aviv Segev, Cecilia Casetta, Sophie E Smart, Johnny Downs, Søren Rahn Christensen, Nikolaj Bak, Bruce J Kinon, Daniel Stahl, James H MacCabe, Richard D Haye. Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine. Journal of psychopharmacology (Oxford, England). 2022-02-25. PMID:35212240. |
a proportion of people with treatment-resistant schizophrenia fail to show improvement on clozapine treatment. |
2022-02-25 |
2023-08-13 |
Not clear |
| Tomoyuki Imai, Sho Ochiai, Takehiro Ishimaru, Hayato Daitoku, Yusuke Miyagawa, Ryuji Fukuhara, Shuken Boku, Minoru Takebayash. A case report: Clozapine-induced leukopenia and neutropenia after mRNA COVID-19 vaccination. Neuropsychopharmacology reports. 2022-02-15. PMID:35166466. |
clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia and is known to cause serious side effects, such as leukopenia and neutropenia. |
2022-02-15 |
2023-08-13 |
Not clear |
| Simon W Rabkin, Jacky K K Tan. Clozapine-Induced Myocarditis: Pathophysiologic Mechanisms and implications for therapeutic approaches. Current molecular pharmacology. 2022-02-14. PMID:35152873. |
clozapine, a superior treatment for otherwise treatment-resistant schizophrenia can produce a potentially life-threatening myocarditis and dilated cardiomyopathy. |
2022-02-14 |
2023-08-13 |
Not clear |
| Manabu Takaki, Yuji Yada, Shinji Sakamoto, Masaki Fujiwara, Yuko Okahisa, Norihito Yamad. A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine. Journal of clinical psychopharmacology. 2022-02-12. PMID:35149611. |
a decrease of neutrophils after covid-19 vaccination in a treatment-resistant patient with schizophrenia taking clozapine. |
2022-02-12 |
2023-08-13 |
Not clear |
| Sandeep Grover, Chandrima Naskar, Subho Chakrabart. Impact of clozapine on disability and course of illness in patients with schizophrenia: A study from North India. Indian journal of psychiatry. vol 63. issue 6. 2022-02-09. PMID:35136257. |
impact of clozapine on disability and course of illness in patients with schizophrenia: a study from north india. |
2022-02-09 |
2023-08-13 |
Not clear |
| Sandeep Grover, Chandrima Naskar, Subho Chakrabart. Impact of clozapine on disability and course of illness in patients with schizophrenia: A study from North India. Indian journal of psychiatry. vol 63. issue 6. 2022-02-09. PMID:35136257. |
the aim of this study was to evaluate the impact of long-term use of clozapine on disability and course of illness among patients with treatment-resistant schizophrenia. |
2022-02-09 |
2023-08-13 |
Not clear |
| Tetsu Tomita, Yui Sakamoto, Manabu Saito, Kojiro Hashimoto, Yasuki Ono, Kazuhiko Nakamur. Two Patients with Schizophrenia Treated with Clozapine Developed Neutropenia After Receiving a COVID-19 Vaccine. International medical case reports journal. vol 15. 2022-02-04. PMID:35115846. |
two patients with schizophrenia treated with clozapine developed neutropenia after receiving a covid-19 vaccine. |
2022-02-04 |
2023-08-13 |
Not clear |
| Tetsu Tomita, Yui Sakamoto, Manabu Saito, Kojiro Hashimoto, Yasuki Ono, Kazuhiko Nakamur. Two Patients with Schizophrenia Treated with Clozapine Developed Neutropenia After Receiving a COVID-19 Vaccine. International medical case reports journal. vol 15. 2022-02-04. PMID:35115846. |
we observed two cases of patients with schizophrenia who were treated with clozapine (250mg/day and 275mg/day, respectively) and showed neutropenia after receiving a covid-19 vaccine (bnt162b2). |
2022-02-04 |
2023-08-13 |
Not clear |